CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 34×, higher than 95% of its Biotechnology peers (median 5.71×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
334.53MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.2660xvs all stocks
52-Week Change
-31.45%vs all stocks
Market Capitalization
334.53MUSDvs all stocks (USD)
Enterprise Value
155.32MUSDvs all stocks (USD)
Forward P/E
-1.02xvs Biotechnology peers
Price to Book (MRQ)
1.86xvs Biotechnology peers
Enterprise to EBITDA
-3.04xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-22.67%vs Biotechnology peers
Return on Equity (TTM)
-33.21%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-51.13MUSDvs all stocks (USD)
Net Income (TTM)
-45.55MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-16.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.75MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Jun 30, 2025Operating Income
-41.77MUSDvs all stocks (USD)
Pre-tax Income
-37.92MUSDFY2025 · Jun 30, 2025Net Income
-37.92MUSDFY2025 · Jun 30, 2025EBIT
-41.77MUSDFY2025 · Jun 30, 2025EBITDA (Income Statement)
-41.30MUSDFY2025 · Jun 30, 2025Research & Development
18.33MUSDFY2025 · Jun 30, 2025Selling, General & Administrative
23.43MUSDFY2025 · Jun 30, 2025EPS (Basic)
-1.05USDFY2025 · Jun 30, 2025EPS (Diluted)
-1.05USDFY2025 · Jun 30, 2025Basic Shares Outstanding
36.21MSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
36.21MSharesFY2025 · Jun 30, 2025Net Income from Continuing Operations
-37.92MUSDFY2025 · Jun 30, 2025Preferred Stock Dividends
0.00USDFY2025 · Jun 30, 2025Operating Cash Flow
-21.02MUSDFY2025 · Jun 30, 2025Free Cash Flow
-21.04MUSDDerived from operating cash flow minus capital expenditure. This filing charges 396K of depreciation against 18K of capital expenditure, and its own free-cash-flow line reads -23.61M.FY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
97.86MUSDFY2025 · Jun 30, 2025Starting Profit (CF Statement)
-37.92MUSDFY2025 · Jun 30, 2025Depreciation & Amortization
396.00KUSDFY2025 · Jun 30, 2025Stock-based Compensation
17.43MUSDFY2025 · Jun 30, 2025Other Non-cash Items
-764.00KUSDFY2025 · Jun 30, 2025Change in Accounts Receivable (CF)
197.00KUSDFY2025 · Jun 30, 2025Change in Other Assets/Liabilities
-356.00KUSDFY2025 · Jun 30, 2025Capital Expenditures
-18.00KUSDFY2025 · Jun 30, 2025Net Investing Cash Flow
-18.00KUSDFY2025 · Jun 30, 2025Other Financing Charges
-2.32MUSDFY2025 · Jun 30, 2025Net Financing Cash Flow
28.14MUSDFY2025 · Jun 30, 2025Shares Outstanding
34.35MSharesUpdated Sep 27, 2026Float Shares
18.45MSharesUpdated Sep 27, 2026Shares Short
2.19MSharesUpdated Sep 27, 2026Short Ratio
16.23daysvs all stocks
Short % of Shares Outstanding
10.96%vs all stocks
% Held by Insiders
2.51%vs all stocks
% Held by Institutions
98.96%vs all stocks
Total Cash (MRQ)
179.97MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.16USDUpdated Sep 27, 2026Total Debt (MRQ)
762.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0043xvs Biotechnology peers
Current Ratio (MRQ)
34.00xvs Biotechnology peers
Book Value per Share (MRQ)
5.14USDUpdated Sep 27, 2026Total Assets
99.59MUSDvs all stocks (USD)
Total Current Assets
98.52MUSDFY2025 · Jun 30, 2025Total Liabilities
2.30MUSDFY2025 · Jun 30, 2025Total Non-current Assets
1.07MUSDFY2025 · Jun 30, 2025Total Non-current Liabilities
495.00KUSDFY2025 · Jun 30, 2025Total Current Liabilities
1.80MUSDFY2025 · Jun 30, 2025Cash
97.74MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents
97.74MUSDFY2025 · Jun 30, 2025Accounts Receivable
33.00KUSDFY2025 · Jun 30, 2025Accounts Payable
201.00KUSDFY2025 · Jun 30, 2025Short-term Debt
354.00KUSDFY2025 · Jun 30, 2025Long-term Debt
495.00KUSDFY2025 · Jun 30, 2025Common Stock (Book)
2.00KUSDFY2025 · Jun 30, 2025Retained Earnings
-228.18MUSDFY2025 · Jun 30, 2025Total Shareholders' Equity
97.30MUSDvs all stocks (USD)
52-Week Low
9.26USDUpdated Sep 27, 202652-Week High
16.76USDUpdated Sep 27, 202652-Week Change
-31.45%vs all stocks
Beta
0.2660xvs all stocks
50-Day MA
12.16USDUpdated Sep 27, 2026200-Day MA
11.98USDUpdated Sep 27, 2026Avg 10-Day Volume
218.16KSharesUpdated Sep 27, 2026Avg 30-Day Volume
160.34KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.9800USDUpdated Sep 27, 2026Other Income / Expense
562.00KUSDFY2025 · Jun 30, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 34×, higher than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 34.00Industry median: 5.71Industry P95: 22.21Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Guangji Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Newron Pharmaceuticals SpA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Hangzhou DPTech Technologies Co., Ltd.
3 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Immuneering Corporation
3 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Standard Lithium Ltd.
3 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration